Biotech Values

[vinmantoo]

One can never pick a bottom but regardless of what the broader market is doing, the fact remains that EDP-235 phase 2 data was quite good. I continue to buy in small amounts and have now increased my shares by 33% since the phase 2 data release. The views of the general public on ENTA are meaningless to me. Some apparently “think” deals can be worked out in a matter of weeks, which is nonsense.